WELCOME LETTER GEST MSK 2027

Word from the Course Directors 2027:

Musculoskeletal disease has reached a scale that can no longer be ignored. Today, an estimated 1.71 billion people worldwide live with musculoskeletal conditions — a figure that continues to climb as populations age and lifestyles change. Knee osteoarthritis alone now affects more than 365 million people globally, and projections suggest that number will grow by nearly 44% by 2035. For too many of these patients, the default path has meant a lifetime of chronic pain, pharmaceutical dependence, or invasive surgery. That reality is changing.​​

The growing body of evidence supporting embolotherapy as a safe, minimally invasive alternative has driven remarkable momentum in the field. What began with knee osteoarthritis has expanded rapidly — adhesive capsulitis, plantar fasciitis, hand osteoarthritis, tendinopathies, and sports injury management are all now within our reach. The interest is genuinely multidisciplinary, reflecting a broader paradigm shift in how we approach chronic musculoskeletal conditions, and the embolotherapy market itself is projected to nearly double over the next decade, underscoring the confidence clinicians and health systems are placing in this approach.​​

Based on the enthusiastic response from our community and the pace at which the science continues to evolve, we are proud to return to Paris for a fifth consecutive year — and to bring you what we believe is our most ambitious and comprehensive program to date.​​

Our goal, as always, is for you to leave Paris not just informed, but ready to act. Success means returning home and implementing evidence-based MSK embolization programs in your practice, collaborating effectively with multidisciplinary teams, selecting appropriate candidates using validated criteria, and — most importantly — transforming the lives of patients who no longer have to accept debilitating pain as inevitable.​​

Welcome to Paris, and welcome to the 5th edition of GEST MSK 2027 – where evidence meets excellence in patient care.​

The Course Directors

In compliance with EBAC guidelines, all speakers/chairpersons participating in this program have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organizing Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CE activities.